Susan Moran
Dr. Moran has over 20 years of industry and academic experience, successfully leading clinical trials from Phase 1 to Phase 3, as well as overseeing NDA and MAA submissions for various investigational products, including the successful approval of Nerlynx. Dr. Moran most recently served as the Chief Medical Officer of RayzeBio, a clinical-stage radiopharmaceutical therapeutics company (acquired by Bristol Meyers Squibb in February 2024). Prior to RayzeBio, she was Chief Medical Officer of QED Therapeutics, an affiliate of BridgeBio Pharma, where she oversaw the clinical development of infigratinib, leading to approval of Truseltiq. Before QED, Dr. Moran was VP and Head of Clinical Development at Puma Biotechnology and previously held senior positions at Takeda (previously Millennium) and Sanofi (former Genzyme). Dr. Moran has played roles in the development, registration, and post-marketing support of products for a number of solid tumors, including bile duct, urothelial, and liver cancer, among others, as well as multiple sclerosis, achondroplasia, and other disorders. She is a board-certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University, and M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine. Dr. Moran currently serves on the board of directors of BioAtla, Inc., a clinical-stage biotechnology company.